Haemonetics Corporation (HAE)

Operating return on assets (Operating ROA)

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Operating income (ttm)	US$ in thousands	164,883	170,195	167,496	178,925	156,033	139,977	132,349	110,127	80,750	40,376	45,150	79,422	89,747	136,929	137,411	128,368	103,351	101,200	88,613	64,950
Total assets	US$ in thousands	2,195,590	2,200,430	2,011,280	1,962,260	1,934,820	1,878,070	1,865,110	1,820,530	1,859,730	1,831,380	1,801,500	1,794,190	1,819,920	1,318,070	1,418,170	1,433,170	1,267,110	1,237,750	1,190,540	1,259,610
Operating ROA		7.51%	7.73%	8.33%	9.12%	8.06%	7.45%	7.10%	6.05%	4.34%	2.20%	2.51%	4.43%	4.93%	10.39%	9.69%	8.96%	8.16%	8.18%	7.44%	5.16%

March 31, 2024 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $164,883K ÷ $2,195,590K
= 7.51%

Haemonetics Corporation's operating return on assets (operating ROA) has exhibited fluctuations over the past several quarters. The trend shows an improvement in performance from the fourth quarter of 2019 to the first quarter of 2020 with operating ROA increasing from 5.16% to 10.39%. This was followed by a gradual decline in the metric until the second quarter of 2021.

However, from the third quarter of 2021 onwards, there has been a significant uptrend in operating ROA, reaching a peak of 9.12% in the second quarter of 2023. Overall, the company's operating ROA has ranged from a low of 2.20% in the first quarter of 2022 to a high of 10.39% in the first quarter of 2020.

The recent values of operating ROA indicate relatively healthy profitability levels compared to previous periods, with the metric hovering around the 7-9% range. It is important for investors and stakeholders to monitor this ratio to assess the company's efficiency in generating profits from its assets over time.